ESPE Abstracts (2016) 86 P-P1-634

Four-Year Results from PATRO Children, a Multi-Centre, Non-Interventional Study of the Long-Term Safety and Efficacy of Omnitrope® in Children Requiring Growth Hormone Treatment

Roland Pfafflea, Shankar Kanumakalab, Hoybye Charlottec, Kristrom Beritd, Zabransky Markuse, Battelino Tadejf & Colle Michelg


aUniversity of Leipzig Medical School, Leipzig, Germany; bRoyal Alexandra Children’s Hospital, Brighton, UK; cKarolinska University Hospital, Stockholm, Sweden; dUmea University, Umea, Sweden; eSandoz International, Holzkirchen, Germany; fUniversity Children’s Hospital, Ljubljana, Slovenia; g25 rue Boudet, Bordeaux, France


Background: PATRO Children is an international, open, longitudinal, non-interventional study of the long-term safety and efficacy of Omnitrope®, a biosimilar recombinant human GH (rhGH).

Objective and hypotheses: The primary objective of PATRO Children is to assess long-term safety of Omnitrope® (particularly the diabetogenic potential of GH in short children born small for gestational age, the risk of malignancies, and other safety signals associated with GH therapy in Prader–Willi syndrome). Long-term efficacy of Omnitrope® is a secondary objective.

Methods: The study population includes infants, children and adolescents treated with Omnitrope® according to local prescribing information. To evaluate safety, all adverse events (AEs) are monitored and recorded. Laboratory values (including glucose metabolism and anti-hGH antibodies) are requested at least once a year. To evaluate efficacy, height standard deviation score, height velocity and height velocity standard deviation score are calculated using height measurements and country-specific reference tables.

Results: As of January 2016, 4675 patients were recruited from 291 sites (14 countries). The mean (S.D.) treatment duration is 30.2 (22.0) months. One case of new-onset type 1 diabetes has been linked to study treatment. No clinically relevant positive anti-hGH antibody titres have been found in patients tested so far. In total, 234 patients (5.0%) have experienced treatment-related AEs and 248 (5.3%) have experienced a serious AE (SAE). SAEs were considered treatment-related in 22 (0.5%) patients. There are no reports of GH-related malignancies and no additional safety concerns. Efficacy data indicate that Omnitrope® has a positive effect on growth parameters in prepubertal children across all indications, irrespective of gender and pre-treatment status.

Conclusion: Results to date show that Omnitrope® is safe and well tolerated across paediatric indications, and is effective in the majority of children. PATRO Children will extend the evidence base for Omnitrope®, and rhGH use in general, in the paediatric population.